Efficacy of alprostadil combined with cilostazol on restenosis after interventional therapy for lower limb arteriosclerosis obliterans
Objective To explore the clinical effect of alprostadil combined with cilostazol in the treat-ment of restenosis after interventional therapy for lower limb arteriosclerosis obliterans(ASO).Methods A total of 98 patients with restenosis after ASO intervention admitted to Lishui People's Hospital in Zhejiang Province from January 2021 to January 2024 were selected and divided into a single group(treated with alprostadil,48 cases)and a combination group(treated with alprostadil combined with cilostazol,50 cases)according to different treat-ment methods.The efficacy,clinical indications[ankle brachial index(ABI),affected limb perfusion volume and transcutaneous partial pressure of oxygen(TcPO2)],serum indexes[matrix metalloproteinase-9(MMP-9)and en-dothelin-1(ET-1)]and occurrence of adverse reactions were compared between groups.Results The total effec-tive rate of treatment in combined group was 98％,which was higher than 85％in single group(x2=5.172,P＜0.05).There was no statistically significant difference in ABI,limb perfusion volume,TcPO2,MMP-9,and ET-1 levels be-tween the two groups before treatment(t=1.581,0.075,0.366,0.321,0.525,P＞0.05).After treatment,ABI,affected limb perfusion volume and affected limb TcPO2 in the two groups were increased,and the indicators in combined group[(0.93±0.23),(28.29±6.31)PU and(31.2±6.5)mmHg]were higher than the single group[(0.81±0.21),(21.46±5.33)PU and(25.2±6.4)mmHg](t=2.694,5.777,4.623,P＜0.05).The levels of MMP-9 and ET-1 were de-creased in both groups,and the two levels in combined group[(12.9±2.0)ng/ml and(57±7)pg/ml]were low-er than single group[(16.5±3.1)ng/ml and(62±8)pg/ml](t=6.878,3.141.P＜0.05).The total incidence rate of adverse reactions in combined group was 14％,and that in single group was 8％(x2=0.789,P＞0.05).Conclusion Al-prostadil combined with cilostazol has significant clinical efficacy in the treatment of patients with restenosis after ASO interventional therapy.It can effectively enhance ABI,increase blood oxygen content and blood perfusion at the distal end of the affected limb,improve lower limb ischemia,and promote vascular remodeling and tissue re-pair,and has high safety.
AlprostadilCilostazolArterial occlusive diseasesRestenosis after interventional thera-pyTreatment outcome
万方数据
维普
